D-0363-2025 Class II Ongoing

Recalled by Eugia US LLC — East Windsor, NJ

FDA drug recall D-0363-2025 was initiated by Eugia US LLC on Apr 10, 2025 and is designated Class II. Reason for recall: cGMP: complaints of crystals not redissolving into solution after warming and shaking the vials. The recall status is ongoing. Affected quantity: 36,816 vials.

Recall details

Product Type
Drugs
Report Date
Apr 23, 2025
Initiation Date
Apr 10, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
36,816 vials

Product description

Testosterone Cypionate Injection, USP, CIII, 200mg per mL, Rx only, 1mL Single-Dose Vial, Distributed by Eugia US LLC, E. Windsor, NJ, Manufactured by: Eugia Specialties Limited, Telangana State, India, NDC 55150-277-01

Reason for recall

cGMP: complaints of crystals not redissolving into solution after warming and shaking the vials.

Distribution pattern

Nationwide USA

Code information

Lot #: 1TC24075A, Exp 11/30/2026.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0363-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0363-2025. Report a data issue: hello@regdatalab.com.